Recurring thrombocytopenia associated with structured treatment interruption in patients with human immunodeficiency virus infection

Clin Infect Dis. 2003 Sep 1;37(5):723-5. doi: 10.1086/376989. Epub 2003 Aug 12.

Abstract

In a structured treatment interruption (STI) trial, 3 of 23 patients in a CD4 cell count-guided treatment arm developed recurring thrombocytopenia associated with the interruption of antiretroviral therapy. All 3 patients had slightly low or normal platelet counts before initiating antiretroviral therapy. STI may play a role in inducing thrombocytopenia in patients with human immunodeficiency virus infection.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • CD4 Lymphocyte Count
  • Drug Administration Schedule
  • HIV Infections / drug therapy*
  • HIV Infections / enzymology
  • HIV Protease Inhibitors / adverse effects
  • HIV Protease Inhibitors / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Platelet Count
  • Randomized Controlled Trials as Topic
  • Recurrence
  • Reverse Transcriptase Inhibitors / adverse effects
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Thrombocytopenia / etiology*

Substances

  • HIV Protease Inhibitors
  • Reverse Transcriptase Inhibitors